keyword
MENU ▼
Read by QxMD icon Read
search

Serebruany

keyword
https://www.readbyqxmd.com/read/29030746/platelet-microrna-for-predicting-acute-myocardial-infarction
#1
Shuhua Li, Long Zhe Guo, Moo Hyun Kim, Jin-Yeong Han, Victor Serebruany
Acute myocardial infarction (AMI) is one of the leading causes of morbidity and mortality worldwide, while early diagnosis still represents an upmost priority. While platelet activation is critical for AMI pathogenesis, the role of platelet microRNAs (pmiRNAs) as biomarkers for AMI is unclear. Furthermore, correlations between the levels of pmiRNAs and indices of platelet activity are also unknown. Expression of platelet miR-1, miR-21, miR-126, miR-150 and miR-223 were prospectively assessed in 20 ST-segment elevation myocardial infarction (STEMI) patients, and 40 healthy volunteers...
October 13, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/29030734/erratum-to-inhibition-of-angiotensin-ii-induced-cardiac-fibrosis-by-atorvastatin-in-adiponectin-knockout-mice
#2
Sun Young Choi, Jong Sung Park, Mee Sook Roh, Chong-Rak Kim, Moo Hyun Kim, Victor Serebruany
In the original published article, Victor Serebruany was designated as the corresponding author in error. The corresponding author is Jong Sung Park. Dr. Park can be reached by email at thinkmed@dau.ac.kr.
October 13, 2017: Lipids
https://www.readbyqxmd.com/read/28988208/meta-analyses-of-incomplete-trial-datasets-unreliable-and-potentially-misleading
#3
EDITORIAL
Victor Serebruany, Nikita Lomakin, Thomas Marciniak
No abstract text is available yet for this article.
October 7, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28898876/filing-sources-after-oral-p2y12-platelet-inhibitors-to-the-food-and-drug-administration-adverse-event-reporting-system-faers
#4
Victor L Serebruany, Vasily Cherepanov, Moo Hyun Kim, Oleg Litvinov, Hector A Cabrera-Fuentes, Thomas A Marciniak
BACKGROUND: The US Food and Drug Administration Adverse Event Reporting System (FAERS) is a global passive surveillance database that relies on voluntary reporting by health care professionals and consumers as well as required mandatory reporting by pharmaceutical manufacturers. However, the initial filers and comparative patterns for oral P2Y12 platelet inhibitor reporting are unknown. We assessed who generated original FAERS reports for clopidogrel, prasugrel, and ticagrelor in 2015...
September 13, 2017: Cardiology
https://www.readbyqxmd.com/read/28810251/a-prospective-randomized-open-label-blinded-endpoint-study-exploring-platelet-response-to-half-dose-prasugrel-and-ticagrelor-in-patients-with-the-acute-coronary-syndrome-hope-tailor-study
#5
Cai De Jin, Moo Hyun Kim, Junghee Bang, Victor Serebruany
BACKGROUND: The optimal dosing of novel oral P2Y12 receptor platelet inhibitors such as prasugrel or ticagrelor is unclear and especially challenging in East Asians. We hypothesize that half-dose prasugrel and ticagrelor may be sufficient for long-term maintenance management in Korean patients with the acute coronary syndrome (ACS) compared with conventional dosages. DESIGN: HOPE-TAILOR (Half Dose of Prasugrel and Ticagrelor in Platelet Response after Acute Coronary Syndromes) is a prospective, randomized, open-label, blinded, endpoint (PROBE) single-center, clinical trial...
August 16, 2017: Cardiology
https://www.readbyqxmd.com/read/28795687/antiplatelet-therapy-aspirin-in-the-elderly-tailored-approaches-ahead
#6
Victor Serebruany, Elena Golukhova
No abstract text is available yet for this article.
October 2017: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/28761683/mortality-and-oral-anticoagulants-in-the-food-and-drug-administration-adverse-event-reporting-system
#7
Victor Serebruany, Vasily Cherepanov, Seth Fortmann, Moo Hyun Kim
OBJECTIVE: The comparative crude death rates (CDR) among non-vitamin K antagonist oral anticoagulants (NOACs) are unknown. Further, whether NOACs improve survival when compared with warfarin is also unclear. We compared CDR co-reported for four NOACs combined or separately versus warfarin within the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. METHODS: We selected CDR from the FAERS database linked to four NOACs and warfarin...
2017: Open Heart
https://www.readbyqxmd.com/read/28697492/incidence-and-causes-for-early-ticagrelor-discontinuation-a-real-world-dutch-registry-experience
#8
Thomas O Bergmeijer, Paul W A Janssen, Mathijs van Oevelen, Dymphie van Rooijen, Thea C Godschalk, Johannes C Kelder, Vera H M Deneer, Victor L Serebruany, Jurriën M Ten Berg
OBJECTIVES: The PLATO trial revealed superiority of ticagrelor over clopidogrel for the prevention of atherothrombotic events in patients with acute coronary syndrome. However, adverse events such as bleeding, dyspnea, and bradycardia were frequently reported, potentially leading to excess early ticagrelor discontinuation (ETD), later confirmed in the PEGASUS trial. We here evaluated the incidence and causes for ETD in a real-world patient cohort in a high-volume nonacademic percutaneous coronary intervention center in the Netherlands...
July 12, 2017: Cardiology
https://www.readbyqxmd.com/read/28663232/are-drug-regulators-really-too-slow
#9
Thomas A Marciniak, Victor Serebruany
No abstract text is available yet for this article.
June 29, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28596132/crusade-score-is-superior-to-platelet-function-testing-for-prediction-of-bleeding-in-patients-following-coronary-interventions
#10
Junghee Bang, Sun Young Choi, Moo Hyun Kim, Victor Serebruany
Hypothetically, diminished platelet reactivity (PR) during dual antiplatelet therapy (DAPT) should cause extra major bleeding events (MBE), although definite evidence is lacking. Multiple scores have been proposed to stratify bleeding risk, but their predictive value during DAPT is unclear. We compared the performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) with PR testing to predict MBE in Korean patients with acute coronary syndrome...
July 2017: EBioMedicine
https://www.readbyqxmd.com/read/28474247/inhibition-of-angiotensin-ii-induced-cardiac-fibrosis-by-atorvastatin-in-adiponectin-knockout-mice
#11
Sun Young Choi, Jong Sung Park, Mee Sook Roh, Chong-Rak Kim, Moo Hyun Kim, Victor Serebruany
Adiponectin is a polypeptide known to inhibit cardiac fibrosis via the activation of ‎adenosine monophosphate-activated protein kinase (AMPK). Statins can also activate AMPK, resulting in the secretion of adiponectin. We determined whether atorvastatin inhibits angiotensin II-induced cardiac fibrosis (AICF) in the presence or absence of adiponectin. Adiponectin knockout (APN-KO, n = 44) and wild type (WT, n = 44) mice were received subcutaneous angiotensin II (1.5 mg/kg/day), and atorvastatin (10 mg/kg/day) was administered orally for 15 days...
May 2017: Lipids
https://www.readbyqxmd.com/read/28267691/vorapaxar-and-amyotrophic-lateral-sclerosis-coincidence-or-adverse-association
#12
REVIEW
Victor L Serebruany, Seth D Fortmann, Daniel F Hanley, Moo Hyun Kim
BACKGROUND: Vorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, is currently approved for post myocardial infarction and peripheral artery disease indications with concomitant use of clopidogrel and/or aspirin. The vorapaxar safety profile was acceptable. However, aside from heightened bleeding risks, excesses of solid cancers and diplopia, there were more amyotrophic lateral sclerosis (ALS) diagnoses after vorapaxar. STUDY QUESTION: To assess the Food and Drug Administration (FDA) reviews on the potential association of vorapaxar with ALS...
March 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/28251238/mortality-and-cancer-after-12-versus-30-months-dual-antiplatelet-therapy-the-korean-outcomes-registry-evaluating-antithrombotics-korea
#13
Victor L Serebruany, Moo Hyun Kim, Hector A Cabrera-Fuentes, Kwangmin Lee, Young Rak Cho, Kyungil Park, Tae Ho Park, Young Dae Kim, Sung-Cheol Yoon
The optimal duration and cancer risks of antiplatelet therapy following percutaneous coronary intervention (PCI) are unclear. We compared cancer and all-cause mortality after dual antiplatelet therapy (DAPT) for the combination of clopidogrel and aspirin (ASA) versus ASA alone over 18 months follow-up in event-free patients at 12 months DAPT from the Health Insurance Review and Assessment (HIRA) dataset via the Korean Outcomes Registry Evaluating Antithrombotics (KOREA). We selected PCI patients who were event free for 12 months and maintained a consistent antiplatelet regimen for 18 more months...
March 2, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28171874/predicting-successful-recanalization-in-patients-with-native-coronary-chronic-total-occlusion-the-busan-cto-score
#14
Cai De Jin, Moo Hyun Kim, Soo Jin Kim, Kwang Min Lee, Tae Hyung Kim, Young-Rak Cho, Victor L Serebruany
BACKGROUND: The optimal strategy to manage chronic total occlusion (CTO) remains unclear. The Japanese CTO multicenter registry (J-CTO) score is an established tool for predicting successful recanalization. However, it does not take into account nonangiographic predictors for final technique success. In the present study, we designed and tested a scoring model called the Busan single-center CTO registry (B-CTO) score combining clinical and angiographic characteristics to predict successful CTO recanalization in Korean patients...
2017: Cardiology
https://www.readbyqxmd.com/read/28161342/excess-ticagrelor-mortality-in-the-food-and-drug-administration-adverse-event-reporting-system-time-to-recount-plato-trial-deaths
#15
EDITORIAL
Victor L Serebruany, Seth D Fortmann, Vasily Cherepanov, Oleg Litvinov, Moo Hyun Kim, Thomas A Marciniak
No abstract text is available yet for this article.
February 1, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28066572/ticagrelor-and-heart-surgery-controversy-we-may-have-better-antiplatelet-options
#16
EDITORIAL
Victor Serebruany, Naida Bulaeva, Elena Golukhova
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27816974/troponin-i-and-d-dimer-for-discriminating-acute-pulmonary-thromboembolism-from-myocardial-infarction
#17
Soo Jin Kim, Moo Hyun Kim, Kwang Min Lee, Tae Hyung Kim, Sun Yong Choi, Min Kook Son, Ji Woen Park, Victor L Serebruany
BACKGROUND: Acute pulmonary thromboembolism (APTE) is a life-threatening condition, often manifesting with chest pain, dyspnea, and increased cardiac biomarkers including cardiac troponin I (CTI) and D-dimer. Therefore, APTE is often misdiagnosed with classical non-ST elevation myocardial infarction (NSTEMI), resulting in unnecessary coronary interventions and a delay of therapy. OBJECTIVES: Our aim was to distinguish APTE from NSTEMI based on CTI and D-dimer levels...
2017: Cardiology
https://www.readbyqxmd.com/read/27698332/the-moving-target-of-clopidogrel-response-variability-new-tricks-of-the-old-dog
#18
EDITORIAL
Victor L Serebruany
No abstract text is available yet for this article.
September 28, 2016: Polskie Archiwum Medycyny Wewnętrznej
https://www.readbyqxmd.com/read/27533756/impact-of-renal-impairment-on-platelet-reactivity-and-clinical-outcomes-during-chronic-dual-antiplatelet-therapy-following-coronary-stenting
#19
Long Zhe Guo, Moo Hyun Kim, Chang Heon Shim, Sun Young Choi, Victor L Serebruany
AIMS: Clinical utilization of dual antiplatelet therapy (DAPT) in patients with renal impairment (RI) following percutaneous coronary interventions (PCI) represents an urgent, unmet need choosing optimal agents, duration of treatment, and potential dose/regimen adjustment. The lack of any large randomized trials specifically in RI patients, and the absence of the uniformed clinical data reporting policy, clouds the reality. Moreover, triaging RI patients is problematic due to ongoing kidney deterioration, and the fact that RI patients are prone to both vascular occlusions and bleeding...
July 2016: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/27517654/thienopyridine-reloading-in-clopidogrel-loaded-patients-undergoing-percutaneous-coronary-interventions-the-praise-study
#20
RANDOMIZED CONTROLLED TRIAL
Long Zhe Guo, Moo Hyun Kim, Eun Seok Shin, Soe Hee Ann, Cai De Jin, Young-Rak Cho, Jong Sung Park, Kyungil Park, Tae-Ho Park, Michael S Lee, Victor L Serebruany
OBJECTIVE: The impact of thienopyridine reloading on clinical outcomes, and residual high platelet reactivity (HPR) is unclear. We sought to compare the HRP-related effect of prasugrel and clopidogrel reloading in the already clopidogrel-loaded patients undergoing percutaneous coronary intervention (PCI). MATERIALS AND METHODS: In this prospective, two-center, randomized, open-label study, patients with HPR who had undergone PCI after a clopidogrel (300-600mg) loading dose (LD) were enrolled...
November 1, 2016: International Journal of Cardiology
keyword
keyword
45374
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"